Shares of Sol-Gel Technologies Ltd. (SLGL) have gained nearly 28 percent year-to-date as the company gears up to face the FDA in the coming months.
Sol-Gel is a clinical-stage dermatology company developing branded and generic topical drug products for the treatment of skin diseases. The company has two product candidates under FDA review - one whose decision date falls in April and the other whose decision date is set for August.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.